Sort
48,018 grants matching “immunotherapy”
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
$370,870Jonathan F Lovell · State University Of New York At Buffalo · R01 · FY2022 · CA
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
$370,870Jonathan F Lovell · State University Of New York At Buffalo · R01 · FY2023 · CA
Developmental Funds
$370,862Rafael Fonseca · Mayo Clinic Rochester · P30 · FY2020 · CA
Amelioration of recurrent herpes keratitis
$370,847Washington University · R01 · FY2003 · EY
A streamlined, high-throughput platform for validation of cancer antigen presentation and isolation of cancer antigen reactive T cells
$370,830Ning Jenny Jiang · University Of Pennsylvania · R33 · FY2023 · CA
In vivo genetic engineering of T-cells for treatment of human diseases
$370,825Sherry Wu · University Of Tx Md Anderson Can Ctr · R35 · FY2017 · GM
In Vivo Prevention of Murine GVHD
$370,819Bruce R. Blazar · University Of Minnesota · R01 · FY2007 · AI
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy
$370,809Andrew J Wiemer · University Of Connecticut Storrs · R01 · FY2025 · CA
T Cell Targeting for GVHD
$370,809Bruce R. Blazar · University Of Minnesota · R01 · FY2009 · HL
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
$370,800Ryan J Sullivan · Massachusetts General Hospital · R01 · FY2019 · CA
Hypoxia-Perfusion Bioreactor for Stem Cell Applications
$370,783Todd A McAdams · Resodyn Corporation · R44 · FY2010 · HL
Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease
$370,781Thomas M Wisniewski · New York University School Of Medicine · R01 · FY2015 · NS
Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease
$370,781Thomas M Wisniewski · New York University School Of Medicine · R01 · FY2019 · NS
Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease
$370,781Thomas M Wisniewski · New York University School Of Medicine · R01 · FY2016 · NS
Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease
$370,781Thomas M Wisniewski · New York University School Of Medicine · R01 · FY2017 · NS
Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease
$370,781Thomas M Wisniewski · New York University School Of Medicine · R01 · FY2018 · NS
Clinical trial development in cancer vaccines
$370,775Samir Khleif · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Optimizing Induction Conditions for Immunotherapeutic CTL
$370,764Carol A Kruse · University Of California Los Angeles · R01 · FY2013 · CA
Genetic Approaches to Enhance the Anti-Tumor Functions of T Lymphocytes
$370,739Michel Sadelain · Sloan-Kettering Inst Can Research · P01 · FY2010 · CA
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer
$370,726Jeffrey Victor Ravetch · Rockefeller University · R01 · FY2025 · CA
Clinical study of GMCI in Pancreatic Cancer
$370,718Estuardo Aguilar-Cordova · Advantagene, Inc · R43 · FY2006 · CA
TCR engineering of human T cells for immunotherapy of hepatocellular carcinoma
$370,716Yukai He · Augusta University · R01 · FY2020 · CA
INTERFERON EPSILON A NEW LOCALIZED IMMUNOTHERAPY FOR OVARIAN CANCER
$370,676Monash University · · FY2025 · Defense Health Agency
Role of hybrid peptide specific T cells in diabetes
$370,649Brian T Fife · University Of Minnesota · P01 · FY2020 · AI
Defining the Role of the Cancer Circadian Clock in Tumor Immunity and Tumorigenesis
$370,636Chi V. Dang · Wistar Institute · R01 · FY2021 · CA